Actavis’ MoxDuo: Can A Generic Firm Drive Growth With A Low-Dose Product?
Executive Summary
Actavis aims to replace its Kadian pain franchise through a deal with QRxPharma for a fixed-dose combination of morphine and oxycodone.
You may also be interested in...
QRxPharma’s Dual-Opioid Therapy MoxDuo Will Face FDA Cmte. Scrutiny
FDA told the company there is no precedent for reviewing a combination product that contains two drugs from the same class. The company’s NDA resubmission for the morphine/oxycodone immediate-release product will include oxygen saturation data from a study originally conducted for European regulators.
Pain Prescriber Education Programs Need Better Coordination, GAO Says
FDA and other federal agencies could better coordinate their efforts to educate prescribers about prescription pain reliever abuse, the Government Accountability Office said.
FDA Restrictions On Rx Acetaminophen Show How Practical Concerns Influence Safety Actions
Because the agency can move faster on Rx products than OTCs, non-prescription products will have higher acetaminophen levels than Rx drugs, at least for the time being.